Trial Profile
Modulation of the Brain Excitatory/Inhibitory (E/I) Balance Through Neuronal and Glial Systems in Autism Spectrum Disorder (ASD
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Nov 2022
Price :
$35
*
At a glance
- Drugs Arbaclofen (Primary)
- Indications Pervasive child development disorders
- Focus Pharmacodynamics
- 14 Apr 2022 Status changed from recruiting to completed.
- 25 Jul 2018 New trial record